Ischaemic colitis in a patient taking meloxicam

被引:15
作者
Garcia, B [1 ]
Ramaholimihaso, F [1 ]
Diebold, MD [1 ]
Cadiot, G [1 ]
Thiéfin, G [1 ]
机构
[1] CHU Robert Debre, Lab Cent Anat & Cytol Pathol, Serv Hepatogastroenterol, F-51092 Reims, France
关键词
D O I
10.1016/S0140-6736(00)04141-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The safety of cyclo-oxygenase 2 (COX-2) preferential inhibitors such as meloxicam is debated, We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis. The endoscopic and histological features were consistent with the diagnosis of ischaemic colitis. Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal. There was no evidence of another cause of colonic ischaemia. We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.
引用
收藏
页码:690 / 690
页数:1
相关论文
共 5 条
[1]  
Ajuebor MN, 2000, AM J PHYSIOL-GASTR L, V279, pG238
[2]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND SEGMENTAL NON-GANGRENOUS COLITIS - A CASE-CONTROL STUDY [J].
COLIN, R ;
HOCHAIN, P ;
CZERNICHOW, P ;
PETIT, A ;
MANCHON, ND ;
BERKELMANS, I .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1993, 5 (09) :715-719
[3]   COX-2 inhibitors [J].
Hawkey, CJ .
LANCET, 1999, 353 (9149) :307-314
[4]  
Patoia L, 1996, BRIT J RHEUMATOL, V35, P61
[5]   COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin [J].
Sigthorsson, G ;
Crane, R ;
Simon, T ;
Hoover, M ;
Quan, H ;
Bolognese, J ;
Bjarnason, I .
GUT, 2000, 47 (04) :527-532